intermediate8 min read

Biotech Dilution and Secondary Offerings Explained

Reviewed by Blane Jackson, DDS, MBA. Educational guide only. See the editorial policy and disclosures.

If you've ever owned a biotech stock and watched it drop 10% overnight for no apparent reason, a secondary offering might be the culprit. For clinical-stage companies, raising capital is as essential as the science itself—but it comes at a cost to existing shareholders. This guide will demystify why biotechs constantly issue new shares, how dilution impacts your investment, and how to read offering terms like a pro. By the end, you'll be able to distinguish between a necessary capital raise and a red flag, and you'll know exactly what to look for before hitting the buy button.

Why Biotechs Need to Raise Capital

Biotech companies, especially those in clinical trials, burn through cash at an astonishing rate. A single Phase 3 trial can cost $100 million or more, and most companies have multiple trials running simultaneously. Unlike tech startups that can bootstrap or generate revenue early, biotechs often have zero revenue for years. They rely on external funding to survive. This funding comes from various sources: venture capital, partnerships, debt, and equity offerings. Secondary offerings—when a company issues new shares to the public—are a common way to raise cash quickly. The trade-off is dilution: each existing share now represents a smaller slice of the company. For investors, understanding this trade-off is crucial. A well-timed offering can fund a pivotal trial that leads to a blockbuster drug, but a poorly timed one can signal desperation or poor financial management.

Key takeaway

Biotechs raise capital through secondary offerings because they need large sums of money to fund clinical trials, and dilution is the price investors pay for potential future success.

Example

Moderna, before its COVID-19 vaccine success, raised billions through multiple secondary offerings to fund its mRNA platform. Each offering diluted shareholders, but the eventual success made it worthwhile.

How Dilution Works

Dilution is the reduction in existing shareholders' ownership percentage due to the issuance of new shares. If a company has 10 million shares outstanding and issues 2 million new shares, the total becomes 12 million. An investor who owned 1 million shares (10% ownership) now owns 8.33% (1 million / 12 million). This percentage drop is permanent unless the company buys back shares. But dilution isn't just about ownership percentage—it also affects earnings per share (EPS) and book value per share. For biotechs that aren't profitable, EPS is less relevant, but the psychological impact on stock price is real. When a secondary offering is announced, the stock often drops because investors anticipate the supply of shares increasing and the value of their shares being diluted. However, if the offering is for a good reason (e.g., funding a promising trial), the stock may recover as the market sees the potential upside.

Key takeaway

Dilution reduces your ownership percentage and can lower the stock price, but it's not always bad if the raised capital is used to create value greater than the dilution cost.

Example

Imagine a biotech with 10 million shares trading at $10. It announces a $50 million offering at $8 per share (a discount). It issues 6.25 million new shares, increasing total to 16.25 million. Your 1% stake becomes 0.615%. The stock might drop to $8.50, but if the trial succeeds, the stock could soar to $30, making the dilution worth it.

Ready to start? Open a Webull account and trade biotech stocks commission-freevia Webull · Affiliate

Types of Secondary Offerings

There are two main types: dilutive and non-dilutive. A dilutive offering is when the company issues new shares, increasing the total share count. This is what most people think of as a secondary offering. Non-dilutive offerings, on the other hand, involve existing shareholders (like founders or early investors) selling their shares. The company doesn't receive any proceeds, and the total share count stays the same—so no dilution. However, a large insider sell-off can signal lack of confidence. Within dilutive offerings, there are variations: bought deals, where an investment bank buys the entire offering and resells it; at-the-market (ATM) offerings, where shares are sold gradually into the market; and registered direct offerings, which are sold to a specific investor. Each has different implications for pricing and timing. For example, ATM offerings can be less disruptive but may drag on for months.

Key takeaway

Not all secondary offerings dilute shareholders—only those that issue new shares. Understanding the type helps you gauge the impact on your investment.

Example

In 2020, many biotechs used ATM offerings to raise capital opportunistically as their stock prices surged. For instance, Novavax raised over $1 billion through ATMs during its COVID-19 vaccine development, causing gradual dilution but funding rapid progress.

Reading Offering Terms

When a company announces a secondary offering, the press release is packed with jargon. Key terms to understand: 'gross proceeds' (total money raised before fees), 'underwriter' (the bank managing the offering), 'discount to market' (the price at which new shares are sold relative to the current price—usually a 5-10% discount), and 'over-allotment option' (also called 'greenshoe,' which allows underwriters to sell up to 15% more shares). The offering price is set after the market closes, and the stock often trades down to that level. Look for the intended use of proceeds: is it for clinical trials, working capital, or debt repayment? Also, check if insiders are participating—if they're buying, it's a positive sign. Finally, consider the company's cash runway: if the offering extends it by less than a year, expect more dilution soon.

Key takeaway

To evaluate an offering, focus on the discount, the use of proceeds, and the resulting cash runway. A reasonable discount and a clear plan for the funds are positive signs.

Example

In June 2023, Sarepta Therapeutics announced a $500 million offering at a 6% discount to fund the launch of its gene therapy Elevidys. The stock dipped initially but recovered as investors saw the potential for the first Duchenne muscular dystrophy gene therapy.

Evaluating the Impact on Your Investment

Before panicking over a secondary offering, do the math. Calculate the dilution percentage: new shares / (old shares + new shares). For example, if a company with 20 million shares issues 5 million new shares, dilution is 20%. Then, estimate the potential upside: if the offering funds a trial that could lead to approval, the market opportunity might dwarf the dilution. Compare the offering price to the company's cash burn rate—how many months of runway does it add? If it's less than 12 months, the company will likely need to raise again, causing further dilution. Also, consider the company's history: does it regularly dilute? Some biotechs are serial diluters, while others raise strategically. Finally, look at the stock's performance post-announcement: a quick recovery suggests investors are confident; a prolonged decline may indicate skepticism.

Key takeaway

Don't automatically sell on a secondary offering. Assess the dilution percentage, the added cash runway, and the potential value creation to make an informed decision.

Example

When Axsome Therapeutics announced a $200 million offering in 2021 to fund its depression drug, the stock initially dropped 8% but then rallied as the drug's launch exceeded expectations, rewarding patient investors.

Red Flags and Green Lights

Not all offerings are created equal. Red flags include: offerings at a steep discount (over 15%), frequent offerings with little progress in between, use of proceeds for 'general corporate purposes' without specifics, and offerings led by insiders selling their own shares. Green lights include: offerings at a small discount, proceeds earmarked for a specific pivotal trial, participation by large institutional investors or insiders, and a clear path to profitability or partnership. Also, consider the company's cash position: if it has less than 6 months of runway, an offering is a necessity, not a choice. In that case, the offering might be less negative than it appears. Conversely, if the company has ample cash but is raising anyway, it might be preparing for a major acquisition or trial expansion—which could be positive.

Key takeaway

Look for offerings that are reasonably priced, have a clear purpose, and are supported by insiders. Be wary of steep discounts and vague use of proceeds.

Example

In 2022, a small biotech announced a 20% discounted offering just months after a previous raise, with no update on its pipeline. The stock plummeted 30% and never recovered—a classic red flag scenario.

Key terms

Secondary Offering

A sale of securities by a company or existing shareholders after the initial public offering (IPO). When the company issues new shares, it's dilutive; when shareholders sell, it's non-dilutive.

Dilution

The reduction in an existing shareholder's ownership percentage due to the issuance of new shares. It can also reduce earnings per share and book value per share.

Bought Deal

A type of offering where an investment bank purchases the entire issue from the company and resells it to investors, taking on the risk of selling the shares.

At-the-Market (ATM) Offering

A method where a company gradually sells new shares into the open market at current prices, often over an extended period, allowing it to raise capital as needed.

Over-Allotment Option (Greenshoe)

An option granted to underwriters to sell up to 15% more shares than the original offering, to cover excess demand and stabilize the stock price.

Cash Runway

The length of time a company can continue operating before it runs out of cash, based on its current cash balance and burn rate.

Next steps

When a biotech announces a secondary offering, calculate the dilution percentage using the formula: new shares / (old shares + new shares).

Read the offering press release and SEC filing (like an 8-K) to find the use of proceeds and the offering discount.

Check the company's cash runway before and after the offering using their latest quarterly report (10-Q) to see how much time the new capital buys.

Monitor insider buying or selling in the offering—insider participation can be a strong signal.

Compare the offering price to the current market price and the company's historical offering patterns to assess if it's a red flag or a green light.

Put this guide to work

Use these free ClinicalInvestor tools to apply what you just learned.

2026 PDUFA Calendar →

Every FDA decision in 2026 with AI investor analysis.

Biotech Catalyst Calendar →

PDUFA dates, Phase 3 readouts, AdComs, and conferences. Free.

Trial Translator →

Paste any ClinicalTrials.gov ID and get a plain-English AI breakdown.

Biotech Screener →

Filter published biotech profiles by area, phase, market cap, and runway.

Company Profiles →

Pipelines, bull and bear cases, and next expected data for every covered biotech.

Keep learning

Understanding Cash Runway in Biotech Stocks →How to Read a 10-K for Biotech Companies →Biotech Risk Management →How to Invest in Biotech Stocks →